Q2 results 2026 today, schedule: The Q2 earnings season for the financial year 2026-27 (Q2 FY27) will continue on Monday, October 26, with 90 companies scheduled to announce their financial results for the July-September quarter.
Among the key companies set to report their quarterly earnings today are Paytm, Mankind Pharma, Tata Consumer Products, ITC Hotels and REC.
Investors will closely monitor these companies’ results for updates on revenue growth, net profit, operating margins and management commentary. The earnings announcements are expected to provide insights into their business performance, management outlook and future growth prospects.
Tata Consumer Q2 results 2026 preview
Kotak Institutional Equities estimates Tata Consumer Products (TCPL) to report 13% year-on-year (YoY) growth in consolidated revenue, compared with 12% in Q1, driven by broad-based growth across its businesses. Domestic tea volumes and value are projected to rise 3% and 1%, respectively, supported by price hikes implemented since June to offset higher tea costs.
The brokerage firm expects gross margin to contract 90 basis points year-on-year and 150 basis points quarter-on-quarter, primarily due to inflation in the India tea and US Coffee businesses. However, EBITDA margin is projected to expand 15 basis points both YoY and sequentially to 13.7%, as operating leverage and cost efficiencies are expected to offset the pressure on gross margins. Net profit (PAT) is estimated to grow 14.3% YoY.
Mankind Pharma Q2 results 2026 preview
Kotak said that Mankind Pharma’s domestic organic business is expected to register around 11% year-on-year (YoY) sales growth in Q2FY27, compared with approximately 10% in Q1FY27, supported by a steady recovery in its base business. Its organic international business is projected to grow 19% YoY, taking overall organic business growth to an estimated 12%.
For BSV, quarterly sales are expected to increase 19% YoY and 8% sequentially. The brokerage also forecasts sales growth of 12% in the prescription (Rx) segment and 7% in the over-the-counter (OTC) segment. Overall, Mankind Pharma’s Q2FY27 sales are estimated to rise 13% YoY and 4% quarter-on-quarter (QoQ).
On the profitability front, Mankind Pharma’s gross margin is expected to improve by 120 basis points YoY to 72.5% in Q2FY27. Consolidated reported EBITDA is projected to grow 19% YoY to ₹1,100 crore, marking a 4% sequential increase. The EBITDA margin is estimated at 26.3%, expanding 140 basis points YoY while remaining flat QoQ.
Disclaimer: We advise investors to check with certified experts before making any investment decisions.
